ATE271880T1 - Methoden zur behandlung von diabetes - Google Patents

Methoden zur behandlung von diabetes

Info

Publication number
ATE271880T1
ATE271880T1 AT00932729T AT00932729T ATE271880T1 AT E271880 T1 ATE271880 T1 AT E271880T1 AT 00932729 T AT00932729 T AT 00932729T AT 00932729 T AT00932729 T AT 00932729T AT E271880 T1 ATE271880 T1 AT E271880T1
Authority
AT
Austria
Prior art keywords
methods
type
diabetes
symptoms
treating diabetes
Prior art date
Application number
AT00932729T
Other languages
English (en)
Inventor
Andreas Sommer
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Application granted granted Critical
Publication of ATE271880T1 publication Critical patent/ATE271880T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00932729T 1999-06-04 2000-05-23 Methoden zur behandlung von diabetes ATE271880T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/326,189 US6040292A (en) 1999-06-04 1999-06-04 Methods for treating diabetes
PCT/US2000/014163 WO2000074710A2 (en) 1999-06-04 2000-05-23 Methods for treating diabetes

Publications (1)

Publication Number Publication Date
ATE271880T1 true ATE271880T1 (de) 2004-08-15

Family

ID=23271175

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00932729T ATE271880T1 (de) 1999-06-04 2000-05-23 Methoden zur behandlung von diabetes

Country Status (15)

Country Link
US (1) US6040292A (de)
EP (1) EP1183042B1 (de)
JP (1) JP2003501397A (de)
KR (1) KR100694737B1 (de)
CN (1) CN1235637C (de)
AT (1) ATE271880T1 (de)
AU (1) AU780400B2 (de)
CA (1) CA2373281C (de)
DE (1) DE60012517T2 (de)
ES (1) ES2222208T3 (de)
IL (1) IL146868A0 (de)
MX (1) MXPA01013384A (de)
NO (1) NO324117B1 (de)
WO (1) WO2000074710A2 (de)
ZA (1) ZA200110408B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
EP1935427B1 (de) * 2000-07-03 2018-03-07 Bristol-Myers Squibb Company Verwendung von löslichen mutanten CTLA4-Mutantenmolekülen
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2422625A1 (en) * 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
RU2403800C2 (ru) * 2004-12-30 2010-11-20 Хилл`С Пет Ньютришн, Инк. Композиция для кошачьего потребления
US8518877B2 (en) * 2007-04-18 2013-08-27 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
EP2352514A4 (de) * 2008-10-29 2012-07-25 Univ Rockefeller Verfahren und kits zur krankheitsbehandlung durch verabreichung des einen insulinähnlichen wachstumsfaktor bindenden proteins 2
MA33248B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Traitement de troubles résistant à l'insuline
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
PL2605771T3 (pl) * 2010-08-16 2018-10-31 Allergan, Inc. Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
NZ255461A (en) * 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
CA2132871A1 (en) * 1993-01-25 1994-08-04 Alan C. Moses Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
EP0723453B1 (de) * 1993-08-03 2000-03-15 Celtrix Pharmaceuticals, Inc. Methode zur behandlung von reproduktionserkrankungen
DE69434403T2 (de) * 1993-09-20 2006-05-04 Celtrix Pharmaceuticals, Inc. Behandlung von immunologischen und hämatologischen Störungen mit IGFBP allein oder als Komplex mit IGF
AU693489B2 (en) * 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
CA2195474A1 (en) * 1994-07-20 1996-02-01 Cedo Martin Bagi Igf/igfbp complex for promoting bone formation and for regulating bone remodeling
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes

Also Published As

Publication number Publication date
HK1044895A1 (en) 2002-11-08
NO324117B1 (no) 2007-08-27
NO20015932D0 (no) 2001-12-04
AU780400B2 (en) 2005-03-17
CA2373281A1 (en) 2000-12-14
KR100694737B1 (ko) 2007-03-14
KR20020020723A (ko) 2002-03-15
US6040292A (en) 2000-03-21
ES2222208T3 (es) 2005-02-01
AU5041100A (en) 2000-12-28
EP1183042A2 (de) 2002-03-06
WO2000074710A3 (en) 2001-06-28
ZA200110408B (en) 2003-03-19
CA2373281C (en) 2010-01-12
WO2000074710A2 (en) 2000-12-14
CN1387440A (zh) 2002-12-25
IL146868A0 (en) 2002-08-14
JP2003501397A (ja) 2003-01-14
CN1235637C (zh) 2006-01-11
MXPA01013384A (es) 2003-09-04
DE60012517D1 (de) 2004-09-02
NO20015932L (no) 2002-01-31
EP1183042B1 (de) 2004-07-28
DE60012517T2 (de) 2005-08-04

Similar Documents

Publication Publication Date Title
DE60012517D1 (de) Methoden zur behandlung von diabetes
ATE503490T1 (de) Monodisperse mischungen und verfahren zur behandlung von diabetes
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
EA200100289A1 (ru) Способ введения инсулинотропных пептидов
DK0915910T3 (da) Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
ATE93138T1 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DE59308848D1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
DE60031951D1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
EP1056458A4 (de) Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
ATE297211T1 (de) Verfahren und zusammensetzung zur behandlung von adenovirale augeninfektionen
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
DE60033569D1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
ATE357914T1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
SE9303068D0 (sv) New use
NZ514691A (en) Method to type prion proteins
GB9818650D0 (en) Therapeutic compounds and methods of making and using the same
UA32295A (uk) Спосіб лікування порушень фертильності у хворих на цукровий діабет

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1183042

Country of ref document: EP